GIP receptor
Participates in glucose-dependent insulin signaling and nutrient-response pathways.
P—03 • Investigational research profile
Retatrutide
A concise educational overview of an investigational single-peptide triple hormone receptor agonist being studied in metabolic research.
Name
Retatrutide
Also known as LY3437943
- Scientific classification
- Single-peptide GIP, GLP-1, and glucagon receptor agonist
- Library family
- Metabolic
- Research status
- Investigational — Phase 3 development
- Regulatory status
- Not FDA approved
Compound overview
A metabolic research peptide with three receptor targets.
Retatrutide is a synthetic investigational peptide designed to activate the receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. It is being studied for obesity, type 2 diabetes, and related metabolic complications.
It remains an investigational compound. Its safety, effectiveness, and long-term clinical role continue to be evaluated in controlled trials.
Mechanism under study
Coordinated triple-receptor signaling
Retatrutide combines activity at three metabolically relevant receptors within one peptide. Researchers are studying how their combined signaling influences appetite, glucose regulation, nutrient handling, and energy balance.
GLP-1 receptor
Influences appetite, glucose-dependent insulin release, and gastrointestinal signaling.
Glucagon receptor
Participates in hepatic energy metabolism and pathways related to energy expenditure.
The contribution of each receptor—and the long-term effect of their combined activation—remains an active area of research.
Current research areas
Questions under investigation
- Body-weight regulation and obesity research
- Glycemic control in type 2 diabetes
- Cardiovascular and kidney outcomes
- Metabolic dysfunction-associated steatotic liver disease
- Obesity-related complications, including sleep apnea and osteoarthritis pain
Evidence summary
Reported research findings
- Substantial weight reduction: Clinical trials have reported significant average body-weight reductions. Phase 3 results varied according to dose, study population, duration, and analysis method.
- Glycemic control: Studies in participants with type 2 diabetes have reported reductions in HbA1c and body weight.
- Cardiometabolic markers: Research has observed improvements in measures such as blood pressure and lipid levels. Whether these changes reduce cardiovascular events remains under investigation.
- Joint health: Phase 3 topline findings have reported improvements in knee osteoarthritis pain among studied participants with obesity. Detailed peer-reviewed evaluation remains important.
- Liver health: A Phase 2a substudy found substantial reductions in liver fat among participants with metabolic dysfunction-associated steatotic liver disease. Larger and longer studies are needed to determine the clinical significance.
These observations come from defined clinical-trial populations and should not be interpreted as guaranteed individual outcomes.
Educational notice
Education, not usage guidance.
This profile is provided for scientific education only. It is not medical advice, a treatment recommendation, dosing information, or instructions for use. Retatrutide is investigational and is not approved by the FDA.
Key scientific referencesComing soon
A curated primary-source reference list will be added during the next educational expansion.